| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-24 |
Sentence |
denotes |
Guillain-Barré syndrome: |
| T2 |
25-94 |
Sentence |
denotes |
The first documented COVID-19–triggered autoimmune neurologic disease |
| T3 |
95-135 |
Sentence |
denotes |
More to come with myositis in the offing |
| T4 |
137-145 |
Sentence |
denotes |
Abstract |
| T5 |
146-155 |
Sentence |
denotes |
Objective |
| T6 |
156-380 |
Sentence |
denotes |
To present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies. |
| T7 |
382-389 |
Sentence |
denotes |
Methods |
| T8 |
390-572 |
Sentence |
denotes |
Eleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. |
